new glp 1 drugs in development GLP-1 Market Size to Hit USD 132.79 Bn by 2035 Emerging Trends in the Development

Drug Targets 11 (2), 9298 (2011)

This is why GLP-1 is valuable when treating type 2 diabetes

After 36 weeks, the 0.5 mg retatrutide group showed a 3.19% body weight reduction, the 4 mg group showed a 10.37% decrease, the 8 and 12 mg groups demonstrated decreases of 16.81% and 16.94% respectively, which were significantly greater than those observed with placebo (3.00%) and 1.5 mg dulaglutide (2.02%) [114]

Next, we estimated the per-protocol effect by accounting for treatment changes and discontinuation, reflecting real-world drug exposure

You feel full longer, which helps reduce cravings and the urge to eat

10.2147/IBPC.S150628 26